Enveda just dropped Phase 1b data for ENV-294 in atopic dermatitis.
85% mean EASI reduction by Day 42. Every. Single. Patient. hit EASI-50 – see the graphic below.
The majority cleared EASI-75 and EASI-90 and saw improvements by Day 8 with no serious adverse events.
And here’s where it gets WILD — responses kept going after patients stopped taking the drug…
I’m sorry, what?
So what is this thing? ENV-294 is a first-in-class oral small molecule. It came out of Enveda’s natural products platform… they built a system that uses mass spec and AI/ML to pull drug candidates from over a million compounds across 38,000 plants.
ENV-294 Phase 1b: EASI response thresholds at Day 42
100%
85%
Day 8
Source: Enveda Biosciences Phase 1b open-label study, moderate-to-severe AD
Enveda is framing ENV-294 as JAK-inhibitor efficacy with an IL-4/IL-13 safety profile.
If that holds in a controlled trial…
Oral. First-in-class mechanism. No boxed warning territory. That’s a differentiated profile in a derm space that’s getting real crowded.
And this isn’t their only program.
They’ve got ENV-6946 in Phase 1 for IBD. ENV-308 in Phase 1 for obesity. ENV-096 for liver conditions. Four clinical programs running at the same time.
$517 million in total funding. Hit unicorn status in 2025 off a $150M Series D. Sanofi is an investor. Former Pfizer CSO Mikael Dolsten is on the board.
They claim they produce dev candidates 4x faster than industry averages. That’s… a claim. But the pipeline velocity kind of backs it up.
Caveats are real. Open-label. Patient numbers not disclosed. We need randomized Phase 2 data before this means anything definitive.
But that Phase 2 is already running.
Watch this one.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
